ABHD10: A Potential Drug Target and Biomarker for Inflammatory diseases

Target Name: ABHD10

NCBI ID: G55347

ABHD10

Other Name(s): acyl-protein thioesterase ABHD10 | abhydrolase domain-containing protein 10, mitochondrial | ABHDA_HUMAN | Alpha/beta hydrolase domain-containing protein 10 | Alpha/beta hydrolase domain-containing protein 10, mitochondrial | Abhydrolase domain-containing protein 10, mitochondrial | mycophenolic acid acyl-glucuronide esterase, mitochondrial | abhydrolase domain containing 10, depalmitoylase | Abhydrolase domain-containing protein 10 | alpha/beta hydrolase domain-containing protein 10, mitochondrial | Palmitoyl-protein thioesterase ABHD10, mitochondrial (isoform 1) | Palmitoyl-protein thioesterase ABHD10, mitochondrial | Acyl-protein thioesterase ABHD10 | ABHD10 variant 1 | Mycophenolic acid acyl-glucuronide esterase, mitochondrial | Abhydrolase domain containing 10, depalmitoylase, transcript variant 1

ABHD10: A Potential Drug Target and Biomarker for Inflammatory diseases

Acyl-protein thioesterase (ABHD10) is a protein that is expressed in various tissues throughout the body, including the liver, muscle, and heart. It plays a crucial role in the regulation of cellular signaling pathways, including the production of pro-inflammatory cytokines. ABHD10 has been implicated in the development and progression of several inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and heart failure.

The Role of ABHD10 in Inflammatory diseases

ABHD10 is a key enzyme in the production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6. These cytokines play a crucial role in the recruitment and activation of immune cells, including T cells, which are responsible for mediating the inflammatory response. ABHD10 has been shown to promote the production and activation of T cells, as well as the production of pro-inflammatory cytokines.

In rheumatoid arthritis, ABHD10 has been shown to contribute to the development and progression of the disease. Studies have shown that ABHD10 is expressed in the human synovial tendons, which are the sites of inflammation in rheumatoid arthritis. Additionally, ABHD10 has been shown to be involved in the regulation of immune cell function and the production of pro-inflammatory cytokines.

In inflammatory bowel disease, ABHD10 has been implicated in the development and progression of the disease. Studies have shown that ABHD10 is expressed in the intestinal epithelial cells, which are the site of inflammation in inflammatory bowel disease. Additionally, ABHD10 has been shown to contribute to the production of pro-inflammatory cytokines, including IL-1 and IL-6.

In heart failure, ABHD10 has been shown to contribute to the development and progression of the disease. Studies have shown that ABHD10 is expressed in the heart muscle cells, which are responsible for maintaining heart function in heart failure. Additionally, ABHD10 has been shown to contribute to the production of pro-inflammatory cytokines, including TNF-伪 and IL-6.

Drug Targeting and Biomarker Development

The potential drug targets for ABHD10 include inhibiting its activity as an enzyme involved in the production of pro-inflammatory cytokines, as well as targeting its role in the regulation of cellular signaling pathways.

One potential drug target for ABHD10 is inhibiting its activity as an enzyme involved in the production of pro-inflammatory cytokines. This could be achieved through the use of small molecules or antibodies that target ABHD10 and prevent its activity from contributing to the production of pro-inflammatory cytokines.

Another potential drug target for ABHD10 is targeting its role in the regulation of cellular signaling pathways. This could be achieved through the use of drugs that modify cellular signaling pathways and inhibit the activity of ABHD10.

Conclusion

ABHD10 is a protein that is involved in the regulation of cellular signaling pathways and has been implicated in the development and progression of several inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and heart failure. The potential drug targets for ABHD10 include inhibiting its activity as an enzyme involved in the production of pro-inflammatory cytokines, as well as targeting its role in the regulation of cellular signaling pathways. Further research is needed to fully understand the role of ABHD10 in inflammatory diseases and to develop effective treatments.

Protein Name: Abhydrolase Domain Containing 10, Depalmitoylase

Functions: Acts as an acyl-protein thioesterase that hydrolyzes fatty acids from acylated residues in proteins (PubMed:31740833). Regulates the mitochondrial S-depalmitoylation of the nucleophilic active site residue of peroxiredoxin-5/PRDX5, a key antioxidant protein, therefore modulating mitochondrial antioxidant ability (PubMed:31740833). Also catalyzes the deglucuronidation of mycophenolic acid acyl-glucuronide, an active metabolite of the immunosuppressant drug mycophenolate (PubMed:22294686)

The "ABHD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets